Q4 Earnings Estimate for BrainsWay Issued By Northland Capmk

BrainsWay Ltd. (NASDAQ:BWAY) – Stock analysts at Northland Capmk increased their Q4 2024 earnings per share (EPS) estimates for shares of BrainsWay in a research report issued to clients and investors on Tuesday, November 12th. Northland Capmk analyst C. Byrnes now forecasts that the company will earn $0.02 per share for the quarter, up from their previous forecast of $0.01. The consensus estimate for BrainsWay’s current full-year earnings is $0.05 per share.

Other research analysts have also issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of BrainsWay in a research report on Monday, October 21st. Northland Securities raised their target price on BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a research note on Thursday, October 3rd.

BrainsWay Price Performance

BWAY opened at $9.53 on Friday. The business has a 50 day simple moving average of $9.19 and a two-hundred day simple moving average of $7.45. The firm has a market capitalization of $158.96 million, a price-to-earnings ratio of 95.31 and a beta of 1.25. BrainsWay has a one year low of $4.16 and a one year high of $10.98.

BrainsWay (NASDAQ:BWAY) last issued its earnings results on Tuesday, November 12th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.03. The company had revenue of $10.50 million during the quarter, compared to analysts’ expectations of $10.07 million. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. During the same period in the prior year, the business posted ($0.01) EPS.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its stake in BrainsWay by 10.3% during the second quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock valued at $110,000 after buying an additional 1,695 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of BrainsWay in the 1st quarter worth $60,000. Perritt Capital Management Inc bought a new stake in shares of BrainsWay in the 2nd quarter worth $121,000. Good Life Advisors LLC increased its holdings in shares of BrainsWay by 65.5% in the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock worth $516,000 after purchasing an additional 22,080 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in shares of BrainsWay by 48.1% in the 2nd quarter. Acadian Asset Management LLC now owns 259,787 shares of the company’s stock worth $1,567,000 after purchasing an additional 84,371 shares in the last quarter. Hedge funds and other institutional investors own 30.11% of the company’s stock.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.